Related Experiment Video

Updated: Jan 29, 2026

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
05:31

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

6.2K

Oncologic outcome of parotid mucoepidermoid carcinoma in pediatric patients

Qigen Fang1, Fei Liu2, Dongjie Seng3

  • 1Department of Head and Neck, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China, qigenfang@126.com.

Cancer Management and Research
|February 19, 2019
PubMed

Insights

Pediatric parotid mucoepidermoid carcinoma (MEC) shows favorable long-term survival. Intraparotid node (IPN) metastasis is a key predictor of recurrence and disease-specific survival in these young patients.

Area of Science:

  • Oncology
  • Pediatric Medicine
  • Head and Neck Surgery

Background:

  • Parotid mucoepidermoid carcinoma (MEC) is a rare malignancy in children.
  • Understanding long-term outcomes is crucial for pediatric cancer care.

Purpose of the Study:

  • To evaluate the long-term oncologic outcomes of pediatric parotid MEC.
  • To identify prognostic factors for recurrence and survival.

Main Methods:

  • Retrospective analysis of 73 patients (<19 years) diagnosed with parotid MEC (1990-2017).
  • Key factors analyzed: intraparotid node (IPN) metastasis, neutrophil-to-lymphocyte ratio (NLR), loco-regional control (LRC), and disease-specific survival (DSS).

Main Results:

  • 10-year LRC and DSS rates were 83% and 88%, respectively.
  • IPN metastasis was significantly associated with recurrence and disease-related death.
  • High NLR showed association with recurrence in univariate but not Cox model analysis.

Conclusions:

  • Pediatric parotid MEC has a favorable long-term survival.
  • IPN metastasis is an independent risk factor for loco-regional recurrence and DSS.
  • Further research is needed to clarify the role of NLR in predicting survival for parotid cancer.
Abstract

Keywords:
mucoepidermoid carcinomaparotid cancerpediatric cancersalivary cancer

More Related Videos

Whole-body PET/MRI of Pediatric Patients: The Details That Matter10:02

Whole-body PET/MRI of Pediatric Patients: The Details That Matter

Published on: December 19, 2017

15.3K
Generation of Comprehensive Thoracic Oncology Database - Tool for Translational Research11:18

Generation of Comprehensive Thoracic Oncology Database - Tool for Translational Research

Published on: January 22, 2011

16.5K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
225
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
285
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
213
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
272
Predicting Reaction Outcomes02:24

Predicting Reaction Outcomes

Kinetics describes the rate and path by which a reaction occurs. In contrast, thermodynamics deals with state functions and describes the properties, behavior, and components of a system. It is not concerned with the path taken by the process and cannot address the rate at which a reaction occurs. Although it does provide information about what can happen during a reaction process, it does not describe the detailed steps of what appears on an atomic or a molecular level. On the other hand,...
10.8K
Outcomes of Glycolysis01:13

Outcomes of Glycolysis

Nearly all the energy used by cells comes from the bonds that make up complex organic compounds. These organic compounds are broken down into simpler molecules, such as glucose. As a result, cells extract energy from glucose over many chemical reactions—a process called cellular respiration.
Cellular respiration can occur aerobically (with oxygen) or anaerobically (without oxygen). In the presence of oxygen, cellular respiration starts with glycolysis and continues with pyruvate...
107.1K